COVID-19 Infection Rates Could Be 10 Times Higher Than Reports Show
The Center for Disease Control (CDC) reported last night (6/24) that the actual number of patients in the United States infected with COVID-19 could potentially be ten times higher. The estimate comes from a serology test that is used to determine if an individual has...
Gilead More than Doubles Original Courses Expectation for Remdesivir
Gilead announced today (6/22) that its expectation for supply of remdesivir increased from 1 million to exceed 2 million by the end of 2020. Remdesivir is on the forefront of fighting the pandemic, helping shorten the length of hospital recovery times for those...
Dexamethasone and COVID-19: The Breakthrough Steroid Saving Severely Ill Patients
Dexamethasone, a cheap and widely used steroid used to reduce inflammation for patients afflicted with arthritis, asthma, some skin conditions, and more, has been recognized as a breakthrough treatment from severely ill COVID-19 patients. When in use, it has shown to...
Johnson & Johnson to Begin Human Trials of COVID-19 Vaccine in July
Johnson & Johnson announced today (6/10) that they will be initiating human trials in the second half of July for the COVID-19 vaccine. The trials are expected to last over the course of two months in both the United States as well as Belgium, and will be...
WHO Prequalifies Rituximab Biosimilar
The World Health Organization (WHO) has prequalified a biosimilar of version of rituximab, which is used to treat certain cancers and autoimmune diseases, created by Celltrion. This drug therapy is the second to achieve prequalification status under the...
FDA Releases MyStudies App for Patient Informed Consent
The FDA released the app FDA MyStudies, which can be found in app stores as COVID MyStudies, for patients to provide informed consent for traditional clinical trials, real-world trials, observational studies, and registries. The app is free, as...
ABOUT US
CSOFT Health Sciences has over 15 years of experience providing end-to-end translation and localization solutions for all stages of the product life cycle, from pre-clinical to post-launch. We also specialize in China market access consulting services, Asian regulatory and eCTD submissions. Our operation is compliant with ISO 17100 and certified by BSI in ISO 9001:2015 and ISO 13485:2016, providing customized solutions to meet the rigorous regulatory requirements in global submission. For more information, please visit: www.csoftintl.com